{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:54:57Z","timestamp":1789440897093,"version":"build-2803163510"},"reference-count":41,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We conducted a single-arm, open-label, single-center phase 1 study to assess the safety and efficacy of multicycle-sequential anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in combination with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy in patients under the age of 65 years with de novo Ph-positive CD19+ B-cell acute lymphoblastic leukemia. Participants were given induction chemotherapy as well as systemic chemotherapy with TKI. Afterward, they received a single cycle of CD19 CAR T-cell infusion and another 3 cycles of CD19 CAR T-cell and CD19+ FTC infusions, followed by TKI as consolidation therapy. CD19+ FTCs were given at 3 different doses. The phase 1 results of the first 15 patients, including 2 withdrawals, are presented. The most common adverse events were cytopenia (13\/13) and hypogammaglobinemia (12\/13). There was no incidence of cytokine release syndrome above grade 2 or immune effector cell-associated neurotoxicity syndrome or grade 4 nonhematological toxicities. All 13 patients achieved complete remission, including 12 patients with a complete molecular response (CMR) at the data cutoff. The relapse-free survival was 84%, and the overall survival was 83% with a median follow-up of 27\u00a0months. The total number of CD19-expressing cells decreased with an increasing CMR rate. CD19 CAR T cells survived for up to 40\u00a0months, whereas CD19+ FTCs vanished in 8 patients 3\u00a0months after the last infusion. These findings could form the basis for the development of an allo-HSCT\u2013free consolidation paradigm. This trial was registered at www.clinicaltrials.gov as #NCT03984968.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009072","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T10:14:21Z","timestamp":1678443261000},"page":"4913-4925","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"7","author":[{"given":"Li-Yun","family":"Chen","sequence":"first","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Gong","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-8616","authenticated-orcid":false,"given":"Ming-Hao","family":"Li","sequence":"additional","affiliation":[{"name":"3Shanghai Unicar-Therapy Bio-Medicine Technology Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Xia","family":"Zhou","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Zhu","family":"Xu","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Sheng","family":"Qian","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qing","family":"Kang","sequence":"additional","affiliation":[{"name":"3Shanghai Unicar-Therapy Bio-Medicine Technology Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-7773","authenticated-orcid":false,"given":"Nan","family":"Xu","sequence":"additional","affiliation":[{"name":"3Shanghai Unicar-Therapy Bio-Medicine Technology Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Yu","sequence":"additional","affiliation":[{"name":"3Shanghai Unicar-Therapy Bio-Medicine Technology Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Qiao","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Long","family":"Tian","sequence":"additional","affiliation":[{"name":"4Gobroad Research Center, Gobroad Medical Group, Bejing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ning","family":"Sun","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[{"name":"3Shanghai Unicar-Therapy Bio-Medicine Technology Co, Ltd, Shanghai, China"},{"name":"5Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Pei","family":"Wu","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4609-616X","authenticated-orcid":false,"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"1","key":"2023091115140860300_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41409-018-0398-8","article-title":"Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?","volume":"54","author":"Aldoss","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2023091115140860300_bib2","volume-title":"NCCN clinical practice guidelines in oncology\u2013Acute lymphoblastic leukemia version 1","year":"2022"},{"issue":"25","key":"2023091115140860300_bib3","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"386","author":"Foa","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2023091115140860300_bib4","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023091115140860300_bib5","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: long-term follow-up of a single-center, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"224","key":"2023091115140860300_bib6","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"15","key":"2023091115140860300_bib7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023091115140860300_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023091115140860300_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9967","key":"2023091115140860300_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2023091115140860300_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","article-title":"CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies","volume":"11","author":"Zhang","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"21","key":"2023091115140860300_bib12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2023091115140860300_bib13","doi-asserted-by":"crossref","first-page":"e144195","DOI":"10.1172\/JCI144195","article-title":"A\u00a0therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T\u00a0cells","volume":"131","author":"Veatch","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2023091115140860300_bib14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2023091115140860300_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2023091115140860300_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"2023091115140860300_bib17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023091115140860300_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"2023091115140860300_bib19","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2023091115140860300_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"2023091115140860300_bib21","doi-asserted-by":"crossref","first-page":"2040620720910023","DOI":"10.1177\/2040620720910023","article-title":"Evaluation and management of measurable residual disease in acute lymphoblastic leukemia","volume":"11","author":"Abou Dalle","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2023091115140860300_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"2023091115140860300_bib23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A\u00a0sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"issue":"23","key":"2023091115140860300_bib24","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"2023091115140860300_bib25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.bbmt.2019.07.037","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO)","volume":"25","author":"Candoni","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2023091115140860300_bib26","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023091115140860300_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023091115140860300_bib28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"355","key":"2023091115140860300_bib29","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"3","key":"2023091115140860300_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"2023091115140860300_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.HS9.0000844300.04335.af","article-title":"P353 forty months update of the GIMEMA LAL2116 (D-ALBA) protocol and ancillary LAL2217 study for newly diagnosed adult Ph+ ALL","volume":"6","author":"Chiaretti","year":"2022","journal-title":"HemaSphere"},{"issue":"21","key":"2023091115140860300_bib32","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMc1712460","article-title":"More on anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Tiberghien","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023091115140860300_bib33","doi-asserted-by":"crossref","first-page":"e004483","DOI":"10.1136\/jitc-2021-004483","article-title":"Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation","volume":"10","author":"Holland","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2023091115140860300_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"2023091115140860300_bib35","doi-asserted-by":"crossref","first-page":"755549","DOI":"10.3389\/fimmu.2021.755549","article-title":"Humanized anti-CD19 CAR-T cell therapy and sequential allogeneic hematopoietic stem cell transplantation achieved long-term survival in refractory and relapsed B lymphocytic leukemia: a retrospective study of CAR-T cell therapy","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"27","key":"2023091115140860300_bib36","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023091115140860300_bib37","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2021-147299","article-title":"Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"138","author":"Myers","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023091115140860300_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2023091115140860300_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a key target of imatinib and dasatinib in T-cell activation","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2023091115140860300_bib40","doi-asserted-by":"crossref","first-page":"e20191009","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"2023091115140860300_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4913\/2077115\/blooda_adv-2022-009072-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4913\/2077115\/blooda_adv-2022-009072-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:14:45Z","timestamp":1694430885000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4913\/494855\/Anti-CD19-CAR-T-cell-consolidation-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009072","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}